Biocon expands US footprint with new Cranbury manufacturing facility

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

 

Bengaluru-based biopharmaceutical giant Biocon has inaugurated its first US manufacturing facility in Cranbury, New Jersey, through its wholly-owned subsidiary Biocon Generics Inc (BGI), marking a key milestone in the company’s global expansion strategy.

 

The new Cranbury facility marks a strategic expansion of the company’s US operations, designed to speed access to essential therapies, strengthen supply reliability, and deepen ties with partners and healthcare providers, ultimately improving care for patients in the States.

 

Kiran Mazumdar-Shaw, chairperson, Biocon Group, said, “More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future.”

   

Biocon expanded its manufacturing footprint in 2023 with the acquisition of an Oral Solid Dosage (OSD) facility from Eywa Pharma Inc.

 

Since then, the company has invested more than $30 million to transform the site into a state-of-the-art plant capable of producing up to two billion tablets annually.

 

A handful of products have already been commercialised from the facility, with several more expected to follow. The investment strengthens its supply chain and supports the company’s push to scale its presence in global markets.

 

Siddharth Mittal, chief executive officer and managing director, Biocon, said, “This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”